ATE449787T1 - Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden - Google Patents
Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurdenInfo
- Publication number
- ATE449787T1 ATE449787T1 AT99970091T AT99970091T ATE449787T1 AT E449787 T1 ATE449787 T1 AT E449787T1 AT 99970091 T AT99970091 T AT 99970091T AT 99970091 T AT99970091 T AT 99970091T AT E449787 T1 ATE449787 T1 AT E449787T1
- Authority
- AT
- Austria
- Prior art keywords
- present
- mage
- ctl clones
- isolated
- ctl
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 241000607142 Salmonella Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 241000607734 Yersinia <bacteria> Species 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/165,863 US6407063B1 (en) | 1998-10-02 | 1998-10-02 | Tumor antigens and CTL clones isolated by a novel procedure |
US09/289,350 US6531451B1 (en) | 1998-10-02 | 1999-04-09 | Tumor antigens and CTL clones isolated by a novel procedure |
PCT/IB1999/001664 WO2000020445A2 (en) | 1998-10-02 | 1999-09-15 | Tumor antigens and ctl clones isolated by a novel procedure |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE449787T1 true ATE449787T1 (de) | 2009-12-15 |
Family
ID=22600796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99970091T ATE449787T1 (de) | 1998-10-02 | 1999-09-15 | Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden |
Country Status (4)
Country | Link |
---|---|
US (2) | US6407063B1 (de) |
JP (1) | JP4722289B2 (de) |
AT (1) | ATE449787T1 (de) |
DE (1) | DE69941719D1 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE272113T1 (de) * | 1994-02-16 | 2004-08-15 | Crucell Holland Bv | Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma |
US20040156861A1 (en) * | 1996-07-11 | 2004-08-12 | Figdor Carl Gustav | Melanoma associated peptide analogues and vaccines against melanoma |
US5965381A (en) * | 1998-03-06 | 1999-10-12 | Ludwig Institute For Cancer Research | Delivery of proteins into eukaryotic cells with recombinant yersinia |
AU1013601A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
DK1282702T3 (da) * | 2000-05-10 | 2007-04-02 | Sanofi Pasteur Ltd | Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf |
US7786278B2 (en) * | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
AU2003278036B2 (en) * | 2002-10-22 | 2009-12-10 | Aventis Pasteur Limited | Anti-cancer vaccines and high-dose cytokines as adjuvants |
CN101124327A (zh) * | 2003-10-08 | 2008-02-13 | 圣诺菲·帕斯图尔公司 | 经修饰的cea/b7载体 |
CA2547635C (en) | 2003-12-12 | 2016-02-09 | Jeffrey Schlom | A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1 |
EP1761662A4 (de) * | 2004-07-01 | 2010-02-03 | Univ California | Proteomik mit hohem durchsatz |
CN101041816B (zh) * | 2006-12-01 | 2010-08-25 | 扬州大学 | 人工抗原递呈细胞及其制备方法 |
ES2845203T3 (es) | 2008-07-01 | 2021-07-26 | Genocea Biosciences Inc | Sistema de análisis de antígenos |
CN109476724B (zh) * | 2016-04-08 | 2023-04-04 | 艾达普特免疫有限公司 | T细胞受体 |
US10859566B2 (en) | 2017-03-20 | 2020-12-08 | Genocea Biosciences, Inc. | Treatment methods |
US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
CA3132840A1 (en) | 2019-03-08 | 2020-09-17 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
MX2021010831A (es) | 2019-03-08 | 2021-12-15 | Obsidian Therapeutics Inc | Composiciones de ligando del cumulo de diferenciación 40 (cd40l) y métodos para regulación ajustable. |
US20200318068A1 (en) * | 2019-04-04 | 2020-10-08 | Immatics US, Inc. | Use of retinoic acid in t-cell manufacturing |
AU2020290522A1 (en) | 2019-06-12 | 2022-01-20 | Obsidian Therapeutics, Inc. | CA2 compositions and methods for tunable regulation |
US20220267398A1 (en) | 2019-06-12 | 2022-08-25 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
WO2021040736A1 (en) | 2019-08-30 | 2021-03-04 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
MX2022002747A (es) | 2019-09-10 | 2022-04-06 | Obsidian Therapeutics Inc | Proteinas de fusion de ca2-il15 para regulacion ajustable. |
MX2022008415A (es) | 2020-01-08 | 2022-08-08 | Obsidian Therapeutics Inc | Composiciones y metodos para la regulacion ajustable de la transcripcion. |
CN111534546A (zh) * | 2020-05-09 | 2020-08-14 | 赛诺(深圳)生物医药研究有限公司 | 一种具有多等位基因p53编码序列的重组腺病毒的制备方法 |
WO2022060806A1 (en) | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5925729A (en) * | 1991-05-23 | 1999-07-20 | Ludwig Institute For Cancer Research | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
EP0656788B1 (de) * | 1992-08-07 | 2006-10-18 | Pharmexa Inc. | Hla bindepeptide und ihre verwendungen |
US5558995A (en) | 1993-01-22 | 1996-09-24 | Ludwig Institute For Cancer Research | Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof |
US6328971B1 (en) | 1993-01-22 | 2001-12-11 | Ludwig Institute For Cancer Research | MAGE-1 derived nona peptides, and compositions thereof |
NZ271774A (en) * | 1993-08-06 | 1998-02-26 | Cytel Corp | Immunogenic peptides from the c-terminus of the mage-1 (melanoma) antigen |
PT879282E (pt) * | 1996-01-17 | 2003-11-28 | Imp College Innovations Ltd | Imunoterapia utilizando linfocitos t citotoxicos (ctl) |
US6265215B1 (en) | 1996-09-13 | 2001-07-24 | Ludwig Institute For Cancer Research | Isolated peptides which complex with HLA-Cw16 and uses thereof |
US5965535A (en) | 1997-09-12 | 1999-10-12 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
CA2323632A1 (en) * | 1998-03-13 | 1999-09-16 | Epimmune Inc. | Hla-binding peptides and their uses |
-
1998
- 1998-10-02 US US09/165,863 patent/US6407063B1/en not_active Expired - Lifetime
-
1999
- 1999-04-09 US US09/289,350 patent/US6531451B1/en not_active Expired - Lifetime
- 1999-09-15 JP JP2000574556A patent/JP4722289B2/ja not_active Expired - Fee Related
- 1999-09-15 AT AT99970091T patent/ATE449787T1/de active
- 1999-09-15 DE DE69941719T patent/DE69941719D1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6531451B1 (en) | 2003-03-11 |
JP2003518911A (ja) | 2003-06-17 |
JP4722289B2 (ja) | 2011-07-13 |
DE69941719D1 (de) | 2010-01-07 |
US6407063B1 (en) | 2002-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE449787T1 (de) | Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden | |
WO2000020445A3 (en) | Tumor antigens and ctl clones isolated by a novel procedure | |
ES2924709T3 (es) | Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer | |
US10968430B2 (en) | Use of specific regulatory T-cells to induce immune tolerance | |
Kimura et al. | cell surface glycoproteins of murine cytotoxic T lymphocytes. I. T 145, a new cell surface glycoprotein selectively expressed on Ly 1-2 (+) cytotoxic T lymphocytes | |
ES2531142T3 (es) | Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden | |
HRP20220131T1 (hr) | Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste | |
DK0512112T3 (da) | Anti-CD4-antistoffer, som blokerer HIV-inducerede syncytier | |
AR018064A1 (es) | Proteina de fusion que consiste en un antigeno asociado a tumores derivado de la familia mage, secuencia de acido nucleico que la codifica, vector que lo comprende, celula huesped que no puede generar un individuo completo transformada con dicho acido nucleico, vacuna que contiene dicha proteina, su | |
EP4253958A3 (de) | Mittel und verfahren zur glykoprofilierung eines proteins | |
BR9809656A (pt) | Composição imunopotencializante | |
NO963918D0 (no) | Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav | |
DK1448229T3 (da) | Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr | |
CN112639136A (zh) | 用于鉴定肿瘤特异性抗原的基于蛋白质基因组学的方法 | |
Golstein et al. | Mouse T cell-mediated cytolysis specifically triggered by cytophilic xenogeneic serum determinants: A caveat for the interpretation of experiments done under “syngeneic” conditions | |
DK0570489T3 (da) | Leverstadium-specifikke peptidsekvenser af P.falciparum, der bærer epitoper, som er i stand til at stimulere T-lymfocytter | |
Rettman et al. | Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors | |
Bergman et al. | Characterization of H+, K+‐ATPase T cell epitopes in human autoimmune gastritis | |
DE602006010934D1 (de) | Verfahren zur Identifizierung von Epitopen in Zusammenhang mit Immunogenität bei Biopharmazeutika | |
Kimura et al. | Cytotoxic T lymphocyte membrane components: an analysis of structures related to function | |
Levin et al. | Potent activation of human T cells by mRNA encoding constitutively active CD40 | |
TW200611706A (en) | Cytotoxic t lymphocyte | |
RU2005106841A (ru) | Эпитопы т-клеток в эритропоэтине | |
DE69833455D1 (de) | Methoden und zusammensetzungen zur erhöhung der immunantwort und zur herstellung von in-vitro monoklonalen antikörpern (mabs) | |
MX2022003432A (es) | Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1117679 Country of ref document: EP |